'Gene Silencer' Drug Shows Promise in Treating Heart Condition - Laboratory Equipment
A study led by UCL researchers found that vutrisiran, a gene silencer drug, reduced hospitalisation and death risk by 28% over 3.5 years in ATTR cardiac amyloidosis patients, with a 33% reduction in non-tafamidis users. Vutrisiran, one of four promising treatments, binds to mRNA to reduce TTR protein production, potentially becoming the new standard of care.
Highlighted Terms
Related News
'Gene Silencer' Drug Shows Promise in Treating Heart Condition - Laboratory Equipment
A study led by UCL researchers found that vutrisiran, a gene silencer drug, reduced hospitalisation and death risk by 28% over 3.5 years in ATTR cardiac amyloidosis patients, with a 33% reduction in non-tafamidis users. Vutrisiran, one of four promising treatments, binds to mRNA to reduce TTR protein production, potentially becoming the new standard of care.